Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Silence Therapeutics PLC

www.silence-therapeutics.com

Latest From Silence Therapeutics PLC

Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate

Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.

Deals M & A

Interview: Mallinckrodt Deal Golden For Silence Therapeutics

The gene silencing specialist has signed a collaboration that CEO David Horn Solomon tells Scrip will help push Silence up among its peers in the RNAi space.

Companies Deals

Alnylam And Silence Settle Over RNAi Patents

Silence will receive a small royalty on future sales of Alnylam’s Onpattro in Europe, and Alnylam is free to use Silence IP in other products.

Intellectual Property Legal Issues

Interview: Silence Therapeutics’ Chair On Why Keeping Quiet Has Done The Biotech No Favors

Silence Therapeutics’ executive chair, Annalisa Jenkins, talks to Scrip about why there’s more to the company than a court case.

Commercial Leadership
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Liposomes
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Ophthalmic
  • Respiratory, Pulmonary
  • Alias(es)
  • SR Pharma PLC
  • Stanford Rook Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Silence Therapeutics PLC
  • Senior Management
  • David Horn Solomon, PhD, CEO
    Rob Quinn, PhD, Interim CFO
  • Contact Info
  • Silence Therapeutics PLC
    Phone: (44) 20 3457 6900
    72 Hammersmith Road
    London, W14 8TH
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register